Skip to main content

Peer Review reports

From: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials

Original Submission
7 May 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
1 Jun 2023 Reviewed Reviewer Report
8 Jun 2023 Reviewed Reviewer Report
7 Sep 2023 Author responded Author comments - Raja Atreya
Resubmission - Version 3
7 Sep 2023 Submitted Manuscript version 3
15 Oct 2023 Reviewed Reviewer Report
18 Oct 2023 Reviewed Reviewer Report
18 Jan 2024 Author responded Author comments - Raja Atreya
Resubmission - Version 4
18 Jan 2024 Submitted Manuscript version 4
1 Feb 2024 Reviewed Reviewer Report
Resubmission - Version 5
Submitted Manuscript version 5
Publishing
7 Feb 2024 Editorially accepted
27 Mar 2024 Article published 10.1186/s12876-024-03163-5

You can find further information about peer review here.

Back to article page